Likewise, clinical trials that test whether magnesium or zinc supplementation can reduce Lp-PLA2 levels and, by extension, advance cardiac outcomes in patients who have this abnormal blood protein but are not symptomatic for heart disease yet are sorely needed. Here, PLA2G7 is linked to heart disorder.